Leflunomide Synergizes with Gemcitabine in Growth Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting

The immunosuppressive agent leflunomide has been used in the treatment of over 300,000 patients with rheumatoid arthritis. Its active metabolite, teriflunomide (Ter), directly inhibits dihydroorotate dehydrogenase (DHODH), an enzyme involved in nucleoside synthesis. We report that Ter not only shows...

Descripción completa

Detalles Bibliográficos
Autores principales: Buettner, Ralf, Morales, Corey, Wu, Xiwei, Sanchez, James F., Li, Hongzhi, Melstrom, Laleh G., Rosen, Steven T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562366/
https://www.ncbi.nlm.nih.gov/pubmed/31211245
http://dx.doi.org/10.1016/j.omto.2019.04.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562366/
https://www.ncbi.nlm.nih.gov/pubmed/31211245
http://dx.doi.org/10.1016/j.omto.2019.04.006

Ejemplares similares